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Abstract
OBJECTIVE: To observe the effects of Bushen Huox-
ue Yin (补肾活血饮, BSHXY) on nuclear transcrip-
tion factor kappa B (NF-κB) and nitric oxide (NO) in
the brain of the Parkinson's disease (PD) model
mouse.
METHODS: Forty-five C57BL/6 mice were randomly
divided into three groups; normal, model and
BSHXY treatment groups. Concentrations of NF-κB
and NO in mouse brain tissue were determined by
ELISA and spectrophotometry, respectively.
RESULTS: NF-κB concentration in brain tissue in
the model group was 14.04±4.38 μg·L-1, which was
higher than that in normal (P<0.01) and BSHXY (P<
0.05) groups. NO content in brain tissue in the mod-
el group was 5.93±0.79 μmol·gprot-1, which was al-
so higher than that in model (P<0.01) and BSHXY
(P<0.01) groups. However, there were no significant
differences in the content of NF-κB and NO be-
tween BSHXY and normal groups (P>0.05).
CONCLUSION: The mechanism of BSHXY for treat-
ment of PD is possibly related to inhibition of
NF-κB activation and decreased NO content in the
brain.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Parkinson's disease (PD) is a retrograde disease of the
central nervous system, which is clinically characterized
mainly by static tremor, bradykinesia, muscular rigidity
and abnormal posture. Presently, definite causes of PD
are unclear and without specific therapeutic approach-
es. Therapy using a dopamine preparation shows obvi-
ous side effects, and after long-term administration,
the therapeutic effect gradually decreases and even
fails[1].Past studies indicate that Bushen Huoxue Yin (补
肾活血饮, BSHXY) shows beneficial therapeutic ef-
fects, significantly improves symptoms and allows re-
duced dosages of Western medicines, thereby relieving
their side effects[2,3]. In addition, BSHXY treatment in-
creases the sensitivity of the dopamine receptor and
promotes release of the dopamine transport protein in
the striatum[4,5] to effectively treat PD. In this study,
changes in nuclear transcription factor kappa B
(NF-κB) and nitric oxide (NO) content in the brain
tissue of the PD model mouse after administration of
BSHXY were observed to investigate the possible mech-
anism of PD treatment.
MATERIALS ANDMETHODS
Experimental animals
Forty-five adult male C57BL/6 mice, sanitary degree,
aged 8–10 weeks, weighing 20±2 g, were supplied by
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the Experimental Animals Center, PLA General Hospi-
tal (Beijing, China) and maintained in a clean animal
house at room temperature (25±2°C) in 40%–50%
relative humidity with a 12 h light-dark cycle. Mice
were allowed free access to water and food.
Main Reagents
1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
(MPTP) was purchased from Sigma Co. USA. Chloral
hydrate solution (10%) was prepared by the Pharma-
ceutical Department of PLA general Hospital. NF-κB
and NO kits were supplied by Beijing Zhongshan Bio-
technique Co. Ltd (Beijing, China).
BSHXY was composed of Rou Cong Rong (Herba Cis-
tanchis), Shan Yu Rou (Fructus Corni), Dang Gui (Ra-
dix Angelicae Sinensis), He Shou Wu (Radix Polygoni
Multiflori), Chi Shao (Radix Paeoniae Rubra), Chuan
Xiong (Rhizoma Chuanxiong), Wu Gong (Scolopen-
dra) and Shi Chang Pu (Rhizoma Acori Graminei),
and supplied and indentified by the Pharmaceutical
Department of PLA General Hospital. Herbs were de-
cocted by a traditional decoction method and concen-
trated in a water-bath at a constant temperature as a de-
coction containing the crude drugs at 1g·mL-1. After
disinfection, the decoction was poured into a sealed
glass bottle and stored at 4°C until use[5]. The BSHXY
dose for mice was 20g·kg-1 according to the calculation
of the dose coefficient of experimental animals and hu-
mans.
Grouping of animals
Mice were randomly divided into three groups, nor-
mal, model and BSHXY groups, with 15 mice in each
group.
Treatment of the animals[6]
Mice in the normal group were intragastrically injected
with saline once a day for 7 days.Themodel groupwas in-
traperitoneally injected with MPTP (30 mg•kg-1, pre-
pared in saline) each day for 7 days, and were intragas-
trically injected with saline 1 h before the intraperitone-
al injection of MPTP in the same volume as that used
for the normal group. Mice in the BSHXY group were
intraperitoneally injected with MPTP each day for 7
days at the same dose used for the model group, and
were intragastrically injected with the BSHXY concen-
trated solution at the same volume used for the normal
group at 1 h before intraperitoneal MPTP injection.
For mice in the model group, approximately 0.5 h after
the first intraperitoneal MPTP injection, short-term ex-
citation and then general vibration, erect hair, tail rais-
ing and after the last injection, reduction of activity,
walking haltingly and slower movement occurred,
which in combination with the results of climbing pole
[7] and hang [8]tests were used to judge modeling suc-
cess.
Mice were sacrificed by decapitation at 6 h after the
last injection on day 7, and then brain tissues were har-
vested[9].
Detection of NF-κB content
NF-κB content in brain homogenates was detected
with an ELISA according to the manufacturer's instruc-
tions. After sacrifice, 0.5 g left brain tissue was harvest-
ed and placed on an ice-cold plate, homogenized with
500 μL saline and then centrifuged at 4000 r·min-1 for
10 min. The supernatant was stored at –80°C. Fifty
microliters of standard solutions, 50 μL samples and
50 μL distilled water were respectively added into
blank microwells in order in an enzyme-labeled plate
coated by an anti-NF-κB specific antibody. One hun-
dred microliters of enzyme-labeled solution was added
to each well except for the control well, then sealed
with sealing gel, incubated at 37°C for 1 h, fully rinsed
with washing solution three times and then dried with
filter paper. Fifty microliters each of color reagents A
and B were added to each well except for the control
well, followed by incubation in a dark box at 37°C for
15 min, and then 50 μL stop solution was added to
each well. OD values were detected by a microplate
reader at 450 nm within 50 min, and a standard curve
was prepared with the OD values as the vertical ordi-
nate and the standard solution concentrations as the
horizontal ordinate. The concentrations of samples
were calculated based on the standard curve according
to the sample OD, and the sensitivity was 1.0
μg·L -1.
Detection of NO content
Right brain tissue was harvest and placed on an
ice-cold plate, rinsed with ice-cold saline and then
dried with filter paper. 500 milligrams of brain tissue
was collected and 4.5 mL cold saline was added to pre-
pare a 10% homogenate that was centrifuged at 2000
r·min-1 for 10 min. The supernatant was collected and
centrifuged again at 10000 r·min-1 for 15 min. Then,
the supernatant was kept for determination of NO con-
tent with spectrophotometry according to the manufac-
turer's instructions.
Statistical analysis
SPSS 11.5 statistical software was used for statistical
analysis. Data were expressed as the mean±standard de-
viation ( xˉ ± s ), and one-way analysis of variance was
used for comparison among groups.
RESULTS
Comparison of NF-κB content in brain tissue
homogenates among groups
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Table1 Comparison of NF-κB content in brain tissue homog-
enates among groups ( xˉ ± s )
Group
Normal
Model
BSHXY
n
15
15
15
NF-κB(μg·L-1)
8.93±2.25
14.04±4.38▲
10.91±3.82*
Notes: ▲P<0.01 vs. normal group; *P<0.05 vs. model group.
Table1 Comparison of NO content in brain tissue homoge-
nates among groups( xˉ ± s )
Group
Normal
Model
BSHXY
n
15
15
15
NO(μmol·gprot-1)
3.27±0.66
5.93±0.79▲
3.91±0.86*
Note: ▲P<0.01 vs. normal group; *P<0.01 vs. model group.
As shown in Table 1, NF-κB content in brain tissue ho-
mogenates was the lowest in the normal group and the
highest in the model group, with significant differences
between normal and model groups (P<0.01) and be-
tween BSHXY and model groups (P<0.05). No signifi-
cant difference was found between BSHXY and nor-
mal groups (P>0.05).
Comparison of NO content in brain tissue
homogenates among groups
As shown in Table 1, NO content in brain tissue ho-
mogenates was the lowest in the normal group and the
highest in the model group, with significant differences
between normal and model groups (P<0.01), and be-
tween BSHXY and model groups (P<0.05). No signifi-
cant difference was found between BSHXY and nor-
mal groups (P>0.05).
DISCUSSION
The main pathological characteristic of PD is involved
in the nigro-striatal system. MPTP is a neurotoxin that
induces degeneration of dopaminergic neurons in the
nigro-striatal system of the C57BL/6 mouse. The com-
pound is highly fat-soluble and very easily passes
through the blood-brain barrier and converts to
1-methyl-4-phenylpyridinium (MPP + ) under the ac-
tion of monoamine oxidase to selectively injure dopa-
minergic neurons in the substantia nigra, hence the
mouse produces symptoms very similar to those of
PD[10]. The C57BL/6 PD mouse model prepared by
MPTP is presently one of the generally recognized PD
animal models at home and abroad, and has been wide-
ly used to study the pathogenesis and treatment of
PD[11].
PD is a commonly observed retrograde disease of the
brain with an unclear cause thus far. Progressive degen-
eration, necrosis and loss of dopaminergic neurons in
the nigro-striatal system, proliferation of gliacytes and
formation of Lewis corpuscle are the main pathological
changes in PD[1]. Presently, its pathogenesis is unclear,
but is possibly related to factors such as genetic inheri-
tance, the action of environmental factors, oxidation
stress, excitatory neurotoxin action and immuno-in-
flammatory responses. In addition, previous studies in-
dicate that NF-κB and NO play a very important role
in the development of PD[12,13].
NF-κB is a group of transcription factors in the Rel
protein family and are present in the form of homolo-
gous or heterologous complexes. In the resting state,
NF-κB protein is localized in the cytoplasm and com-
bines with inhibitor kappa B (IκB) in a non-active
state. NF-κB can be activated by specific cytokines,
protein kinases, oxidizing agents, viruses, lipopolysac-
charides and ultraviolet radiation[14]. In the central ner-
vous system, NF-κB is widely expressed and activated
by numerous neurotrophic factors, cytokines and cyto-
toxins. Activated NF-κB can induce the expression of
cytokines, growth factors, acute proteins, chemotactic
factors, immuno-receptors and transcription factors,
which participate in various pathological courses of im-
mune and inflammatory responses of diseases[15]. Autop-
sy of PD patients indicates increased NF-κB expression
in the nucleus of dopaminergic neurons in the substan-
tia nigra[16]. The results of the present study indicated
that NF-κB content in the model group was signifi-
cantly higher than that in the normal group (P<0.01),
suggesting that NF-κB in the brain tissue of the model
group was activated. After treatment with BSHXY in
the BSHXY group, NF-κB content was not significant-
ly higher compared with that in the normal group (P>
0.05), but was significantly higher than that in the
model group (P<0.05), indicating that BSHXY decreas-
es the expression of harmful factors possibly via inhibi-
tion of NF-κB activation to treat PD.
NO is a small signaling molecule with broad biological
effects and is produced from the de-guanidinium
group of L-arginine, catalyzed by inducible nitric oxide
synthase (iNOS) in the body in a normal state and is
sustained in a dynamic balance in tissues[17]. Almost all
neural cells in the brain are able to synthesize NO, but
excessive NO can cause toxicity-induced cell injury. A
previous study indicated that high levels of NO play an
important role in the pathogenic mechanisms of PD[13].
NO also can disrupt membrane structures and cause
dysfunction of cell and mitochondrial membranes,
leading to neural cell death. In addition, NO acts on
neural cell DNA by introducing breakages in single-
and double-stranded DNA followed by cross-linking
that leads to defects and erroneous pairing of DNA bas-
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es resulting in cellular necrosis and apoptosis. It can al-
so induce neural cell injury via activating ADP-ribose
synthase (PARS) and then by the energy-consuming re-
action of PARS. NO itself as a free radial shows cellu-
lar toxicity that induces cell injury. In addition, it can
interfere with the energy metabolism of cells and initi-
ate apoptosis. From these observations, it can be in-
ferred that NO is involved in DA neuron injury via
multiple pathways. In this study, we showed that NO
content in the model group was significantly higher
than that in the normal group (P<0.05), indicating
that a large amount of NO is produced in the brain tis-
sue of the model group. In the BSHXY group, NO
content was similar to that of the normal group (P>
0.05) and significantly lower than that in the model
group (P<0.05), suggesting that BSHXY treats PD pos-
sibly via decreasing NO content and reducing neural
toxicity.
Previous studies found that BSHXY shows beneficial ef-
fects on PD patients and promotes cellular repair in
the substantia nigra and increases dopaminergic neu-
ron activity in PD model animals[18,19]. These effects
may possibly occur via inhibition of NF-κB activation
and decreased NO content in the brain, which protects
neurons from injury, thereby effectively treating PD.
NF-κB is closely associated with iNOS, a rate-limited
enzyme of NO synthesis, and regulates transcription of
iNOS mRNA. NO, a product of iNOS, has a feedback
inhibitory action on the activation of NF-κB[20]. How-
ever, in this study, NF-κB and NO content in the
mouse brain of the model group increased, but de-
creased respectively after treatment with BSHXY, thus
the interaction between them requires further study.
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